ADOCIA a biotechnology company dedicated to protein delivery

  • Contact
  • Linkedin
  • Twitter
  • Youtube
  • RSS
  • LANGUAGES
    • English English
    • Français Français
  • Presentation
    • About Adocia
    • Founders
    • Management
    • Board of Directors
    • Team
    • Scientific Advisory Board
    • Symbol
  • Technology
    • BIOCHAPERONE®
    • Intellectual property
    • Publications
  • Products
    • Pipeline
    • BIOCHAPERONE® LISPRO
    • BIOCHAPERONE® COMBO
    • M1Pram
    • BIOCHAPERONE® GLUCAGON
    • BIOCHAPERONE® Gla GLP-1
    • BioChaperone® Glucagon GLP-1
    • Cell Therapy: AdoShell Islets
  • Partnering
    • Licensing Opportunities
    • Contact
  • Financials
    • Home Investors
    • Regulated Information
    • Documentation
    • Shareholders
    • Shareholders meeting
    • Governance
    • Investors Contact
  • Careers
    • Working at Adocia
    • HR Policy
    • Gender Equality index
    • Offers
  • News & Events
    • Press Releases
    • Upcoming Events

BIOCHAPERONE® GLARGINE GLP-1 

BIOCHAPERONE® GLARGINE GLP-1: a simple intensification option over basal insulin

photo-glargineBasal insulin remains an essential treatment for patients with type 2 diabetes who do not reach glycemic targets on oral antidiabetic agents. However, by some estimates, up to 50% of people with diabetes who use basal insulin as their only injectable treatment do not reach their glycemic target1.

To address the need for intensification of treatment from basal insulin alone or GLP-1 alone, Adocia initiated a preclinical BioChaperone program in the preclinical stage, combining basal insulin (insulin glargine) with GLP-1 receptor agonists (“GLP1”, eg liraglutide). This program takes advantage of Adocia’s expertise in the solubilization of insulin glargine at physiological pH.

1 Sanofi, Corporate presentation Q3 2015

Products

  • Pipeline
  • BIOCHAPERONE® LISPRO
  • BIOCHAPERONE® COMBO
  • M1Pram
  • BIOCHAPERONE® GLUCAGON
  • BIOCHAPERONE® Gla GLP-1
  • BioChaperone® Glucagon GLP-1
  • Cell Therapy: AdoShell Islets

A la Une / Spotlight

  • 100 years ago, the first insulin injection saved Leonard Thompson

    This week, it has been 100 years since 14-year-...
  • Upcoming Investor Conferences – January 2022

    Dear investors, Adocia invites you to meet mana...

  • Home
  • Terms Of Use
  • Privacy Policy
  • Contact
ADOCIA a biotechnology company dedicated to protein delivery

Copyright ADOCIA © 2018

TOP